The early detection and treatment controversy in schizophrenia research

Current Opinion in Psychiatry

Volumn 16, Issue 2, 2003, Pages 175-179

  Verdoux, Hélène ^a,b   Cougnard, Audrey ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

Early intervention; Early treatment; Ethics; Psychosis; Usefulness

Indexed keywords

NEUROLEPTIC AGENT;

COGNITIVE THERAPY; DISEASE DURATION; EARLY DIAGNOSIS; HEALTH EDUCATION; HUMAN; LOW DRUG DOSE; MEDICAL ETHICS; MEDICAL RESEARCH; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SCREENING TEST;

EID: 0037338045     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200303000-00006     Document Type: Review

References (36)

1. Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992; 55:4-15.
2. Malla A, Norman R. Early intervention in schizophrenia and related disorders: advantages and pitfalls. Curr Opin Psychiatry 2002; 15:17-23. This is an excellent and exhaustive review summarizing the literature on early intervention in psychosis until 2001.
3. Lieberman J, Perkins D, Beiger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches [Review]. Biol Psychiatry 2001; 50:664-897. This is a review on the state of knowledge on the potental neurotoxicity of untreated psychosis.
4. Aitamura AC, Bassetti R, Sassella F, et al. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 2001; 52:29-36.
5. Black K, Peters L, Rui Q, et al. Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophr Res 2001; 47:215-222.
6. McGtashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001; 27:563-570. This is a plea highlighting the need for further deveropment of early intervention research.
7. Warner R. The prevention of schizophrenia: what interventions are safe and effective? Schizophr Bull 2001; 27:551-562. This is a very important paper demonstrating that the risks and benefits of early intervention have to be assessed from a public health perspective.
8. Verdoux H, Liraud F, Bergey C, et al. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr Res 2001; 49:231-241.
9. Warner R. Response to McGorry and Edwards. Schizophr Bull 2002; 28:182-185.
10. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizaphrenia prodrome: is it presently ethical? Schizophr Res 2001; 51:31-38. This is a review of some unsolved questions regarding early intervention in prodromal subjects.
11. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001; 51:17-29.
12. Schaffner KF, McGorry PD. Preventing severe mental illnesses - new prospects and ethical challenges. Schizophr Res 2001; 51:3-15. This is a review on the state of knowledge of the risks and benefits of early intervention.
13. Sevy S, Robinson DG, Holloway S, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104:367-374.
14. Lester H. 10-Minute consultation: first episode psychosis [Comment]. BMJ 2001; 323:1408.
15. Sandor A, Courtenay K. First episode psychosis. Patients must be asked about suicidal ideation and substance misuse [Comment]. BMJ 2002; 324:976.
16. Courtenay K. First episode psychosis. GPs must assess patients' risk behaviour [Comment]. BMJ 2002; 324:976.
17. Verdoux H, Liraud F, Gonzales B, et al. Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatr Scand 1999; 100:389-395.
18. Verdoux H, Liraud F, Gonzales B, et al. Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2001; 103:347-354.
19. Lareen TK, McGlashan TH, Johannessen JO, et al. Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. Am J Psychiatry 2001; 158:1917-1919. This is the first population-based study showing that an educational programme on early psychosis contributes to shortening of the DUP.
20. McGorry P. Rationale for and the substantial potential benefits linked to early recognition and optimal treatment of psychotic disorders, specifically schizophrenia. Acta Psychiatr Scand 2001; 103:402-403.
21. Heinssen RK, Perkins DO, Appelbaum PS, et al. Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000. Schizophr Bull 2001; 27:571-583. This is a synthesis of the conclusions of a National Institute of Mental Health workshop on the ethical aspects of early intervention.
22. Verdoux H, Maurice-Tison S, Gay B, et al. A survey of delusional ideation in primary care patients. Psychol Med 1998; 28:127-134.
23. Verdoux H, Van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 2002; 54:59-65.
24. Verdoux H, Van Os J, Maurice-Tison S, et al. Is early adulthood a critical developmental stage for psychosis proneness? A survey of delusional ideation in normal subjects. Schizophr Res 1998; 29:247-254.
25. Simon AE, Ferrero FP, Merlo MC. Prodromes of first-episode psychosis: how can we challenge nonspecificity? Compr Psychiatry 2001; 42:382-392.
26. Cougnard A, Salmi R, Verdoux H. A decade of debate on early intervention in psychosis: a systematic review of criteria for assessing screening usefulness. Schizophr Res (in press).
27. Verdoux H. Have the times come for early intervention in psychosis? Acta Psychiatr Scand 2001; 103:321-322.
28. McGorry PD, Edwards J. Response to 'The prevention of schizophrenia: what interventions are safe and effective?' [letter]. Schizophr Bull 2002; 28:177-180; discussion 81-85.
29. Rose G. The strategy of preventive medicine. Oxford: Oxford University Press; 1992.
30. Woods S, Miller T, Davidson L, et al. Estimated yield of early detection of prodromal or first episode patients by screening first degree relatives of schizophrenic patients. Schizophr Res 2001; 52:21-27. This is a study illustrating the fact that early detection focused on subjects at genetic risk of schizophrenia will have little effectiveness in detecting new cases of schizophrenia.
31. Walter G, Wiltshire C, Anderson J, et al. The pharmacologic treatment of the early phase of first-episode psychosis in youths [Review]. Can J Psychiatry 2001; 46:803-809. This is a review on psychotropic medications in first-episode psychosis, highlighting the paucity of data on the effects and risks of pharmacological treatment in adolescents.
32. McGorry PD, Yung A, Phillips LJ, et al. A randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928. A 6-month open randomised controlled trial study showing that transition rates were lower in subjects with at-risk mental state treated by low doses of antipsychotic and cognitive therapy compared to subjects treated by supportive psychotherapy.
33. Gøtzsche P. Medicalisation of risk factors. BMJ 2002; 324:890-891. This is an interesting comment on the usefulness of disease screening.
34. Degrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia [Review]. Schizophr Res 2001; 51:77-86. This is an excellent review of the ethical and legal aspects of informed consent in early intervention research, especially in minors.
35. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res 2001; 51:47-54.
36. Moynihan R, Heath I, Henry D, et al. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324:886-891. This is a helpful paper illustrating the influence of drug companies on the definition of the boundaries of treatable diseases.